

## Supplementary Materials

**Table S1.** Temporal changes of serum levels of perforin, granzyme A, and granzyme B in the mild group of SARS-CoV-2 patients and healthy control participants.

	Healthy controls (n=20)	Mild group (n=77)	P-value	Time from symptom onset					
				Early phase (n=28)	P-value	Mid Phase (n=24)	P-value	Late phase (n=25)	P-value
Perforin (ng/mL)	5.03 ±2.78	3.39 ±3.54	< 0.01	2.93 ± 2.51	<0.001	3.17 ± 3.20	0.06	4.14 ± 3.76	0.26
Granzyme A (pg/mL)	143.42 ±96.27	107.69 ±81.95	0.25	105.48 ± 92.68	0.48	93.41 ± 90.47	0.30	124.20 ± 112.29	0.19
Granzyme B (pg/mL)	212.98 ±147.57	32.81 ±41.06	0.28	25.94 ± 20.14	0.55	39.79 ± 24.08	0.92	35.71 ± 21.38	0.09

Note: Values were presented in mean ± standard deviation. P-values were estimated by the t-test or Mann-Whitney U tests comparing each phase of SARS-CoV-2 infection and severity with the healthy controls after the levels were transformed log 10. Based on days after symptom onset, the period of infection was classified as follows; Early phase, 1 – 5 days; Mid-phase, 6 – 10 days; Late phase, 11 – 18 days. Based on the clinical severity score from World Health Organization, disease severity was classified into the mild groups.

**Table S2.** Temporal changes of serum levels of perforin, granzyme A, and granzyme B in the moderate-severe group of SARS-CoV-2 patients, and healthy control participants.

	Healthy controls (n=20)	Moderate-severe group (n=23)	P-value	Time from symptom onset					
				Early phase (n=8)	P-value	Mid Phase (n=7)	P-value	Late phase (n=8)	P-value
Perforin (ng/mL)	5.03 ±2.78	2.74 ±2.06	0.05	2.49 ± 1.99	0.052	2.76 ± 2.42	0.63	2.94 ± 5.29	0.37
Granzyme A (pg/mL)	143.42 ±96.27	106.81 ±53.10	0.03	111.81 ± 51.10	0.04	93.72 ± 49.11	0.02	114.92 ± 53.96	0.053
Granzyme B (pg/mL)	212.98 ±147.57	20.96 ±13.40	0.19	18.79 ± 16.80	0.23	17.28 ± 14.71	0.35	26.79 ± 15.78	0.22

Note: Values were presented in mean ± standard deviation. P-values were estimated by the t-test or Mann-Whitney U tests comparing each phase of SARS-CoV-2 infection and severity with the healthy controls after the levels were transformed log 10. Based on days after symptom onset, the period of infection was classified as follows; Early phase, 1 – 5 days; Mid-phase, 6 – 10 days; Late phase, 11 – 18 days. Based on the clinical severity score from World Health Organization, disease severity was classified into the moderate-severe groups.